Here, we performed an in vivo CD8+ T cell CRISPR screening in primary tumours, metastatic niches and secondary lymphoid organs complemented by single-cell RNA sequencing (scRNA-seq) to identify metabolic determinants governing CD8+ T cell functionality and enhancing responsiveness to anti-PD-1 treatment in solid refractory tumours. This evidence concerns the gene PDCD1 and neoplasm.